Early diagnostic protein biomarkers for breast cancer: How far have we come?

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 1-12

  Opstal Van Winden, Annemieke W J ^a,b   Vermeulen, Roel C H ^a,c   Peeters, Petra H M ^a,d   Beijnen, Jos H ^b,e   Van Gils, Carla H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Biomarkers; Breast cancer; Early diagnosis; MALDI TOF MS; Proteomics; SELDI TOF MS

Indexed keywords

COMPLEMENT COMPONENT C5A [DEARGININE]; IHIH4 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANALYTIC METHOD; BREAST CANCER; CANCER CLASSIFICATION; CANCER STAGING; DISEASE CLASSIFICATION; DISEASE HETEROGENEITY; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

AMINO ACID SEQUENCE; ANIMALS; BLOOD PROTEINS; BREAST NEOPLASMS; COMPLEMENT C3A; EARLY DETECTION OF CANCER; FEMALE; GLYCOPROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84863982978     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1907-2     Document Type: Review

References (65)

1. D Schopper C de Wolf 2009 How effective are breast cancer screening programmes by mammography? Review of the current evidence Eur J Cancer 45 1916 1923 19398327 10.1016/j.ejca.2009.03.022
2. WJ Louwman AC Voogd JA van Dijck, et al. 2008 On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975-2004: a long-term population-based study in southeastern Netherlands Cancer Causes Control 19 97 106 18038250 10.1007/s10552-007-9075-8 1:STN:280: DC%2BD1c%2FjvFOlug%3D%3D
3. NF Boyd H Guo LJ Martin, et al. 2007 Mammographic density and the risk and detection of breast cancer N Engl J Med 356 227 236 17229950 10.1056/NEJMoa062790 1:CAS:528:DC%2BD2sXnslSjsg%3D%3D
4. MT Mandelson N Oestreicher PL Porter, et al. 2000 Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers J Natl Cancer Inst 92 1081 1087 10880551 10.1093/jnci/92.13.1081 1:STN:280:DC%2BD3cvivFyrtA%3D%3D
5. TM Kolb J Lichy JH Newhouse 2002 Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27, 825 patient evaluations Radiology 225 165 175 12355001 10.1148/radiol.2251011667
6. National evaluation of breast cancer screening in the Netherlands 1990-2007 (2010) Twelfth evaluation report
7. M Merchant SR Weinberger 2000 Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry Electrophoresis 21 1164 1177 10786889 10.1002/(SICI)1522-2683(20000401)21:6<1164::AID- ELPS1164>3.0.CO;2-0 1:CAS:528:DC%2BD3cXis12ku7g%3D
8. MC Gast JH Schellens JH Beijnen 2009 Clinical proteomics in breast cancer: a review Breast Cancer Res Treat 116 17 29 19082706 10.1007/s10549-008- 0263-3 1:CAS:528:DC%2BD1MXntFakur0%3D
9. Y Hu S Zhang J Yu J Liu S Zheng 2005 SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer Breast 14 250 255 16085230 10.1016/j.breast.2005.01.008
10. S Becker LH Cazares P Watson, et al. 2004 Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer Ann Surg Oncol 11 907 914 15383419 10.1245/ASO.2004.03.557
11. C Belluco EF Petricoin E Mammano, et al. 2007 Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer Ann Surg Oncol 14 2470 2476 17594124 10.1245/s10434-007-9354-3
12. A Vlahou C Laronga L Wilson, et al. 2003 A novel approach toward development of a rapid blood test for breast cancer Clin Breast Cancer 4 203 209 14499014 1:CAS:528:DC%2BD3sXotlels7w%3D
13. AK Callesen W Vach PE Jorgensen, et al. 2008 Combined experimental and statistical strategy for mass spectrometry based serum protein profiling for diagnosis of breast cancer: a case-control study J Proteome Res 7 1419 1426 18303830 10.1021/pr7007576 1:CAS:528:DC%2BD1cXisFWksr0%3D
14. ME de Noo A Deelder M van der Werff A Ozalp B Mertens R Tollenaar 2006 MALDI-TOF serum protein profiling for the detection of breast cancer Onkologie 29 501 506 17068384 10.1159/000095933
15. C Laronga S Becker P Watson, et al. 2003 SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers Dis Markers 19 229 238 15258337 1:CAS:528:DC%2BD2cXls1anurs%3D
16. L Pusztai BW Gregory KA Baggerly, et al. 2004 Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma Cancer 100 1814 1822 15112261 10.1002/cncr.20203 1:CAS:528:DC%2BD2cXkt1Sgs7o%3D
17. S Shin L Cazares H Schneider, et al. 2007 Serum biomarkers to differentiate benign and malignant mammographic lesions J Am Coll Surg 204 1065 1071 17481542 10.1016/j.jamcollsurg.2007.01.036
18. A Lebrecht D Boehm M Schmidt H Koelbl FH Grus 2009 Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry to detect breast cancer markers in tears and serum Cancer Genomics Proteomics 6 75 83 19451091 1:CAS:528:DC%2BD1MXmtV2lsLo%3D
19. J Li Z Zhang J Rosenzweig YY Wang DW Chan 2002 Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer Clin Chem 48 1296 1304 12142387 1:CAS:528:DC%2BD38XlslKktrg%3D
20. Opstal-van Winden AW, Beijnen JH, Loof A et al (2011) Search for breast cancer biomarkers in fractionated serum samples by protein profiling with SELDI-TOF MS. J Clin Lab Anal (accepted)
21. J Solassol P Rouanet PJ Lamy, et al. 2009 Serum protein signature may improve detection of ductal carcinoma in situ of the breast Oncogene 29 550 560 19855429 10.1038/onc.2009.341
22. J Li R Orlandi CN White, et al. 2005 Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry Clin Chem 51 2229 2235 16223889 10.1373/clinchem.2005.052878 1:CAS:528:DC%2BD2MXht1yks7fN
23. C Mathelin A Cromer C Wendling C Tomasetto MC Rio 2006 Serum biomarkers for detection of breast cancers: a prospective study Breast Cancer Res Treat 96 83 90 16322896 10.1007/s10549-005-9046-2 1:CAS:528:DC%2BD28XivVentr4%3D
24. Y Fan J Wang Y Yang, et al. 2010 Detection and identification of potential biomarkers of breast cancer J Cancer Res Clin Oncol 136 1243 1254 20237941 10.1007/s00432-010-0775-1 1:CAS:528:DC%2BC3cXns1yls7c%3D
25. MC Gast CH van Gils LF Wessels, et al. 2009 Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS Oncol Rep 22 205 213 19513525 10.3892/or-00000426 1:CAS:528:DC%2BD1MXoslymsLY%3D
26. AW van Winden MC Gast JH Beijnen, et al. 2009 Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study BMC Med Genomics 2 4 19152674 10.1186/1755-8794-2-4
27. JK Habermann UJ Roblick BT Luke, et al. 2006 Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors Gastroenterology 131 1020 1029 17030172 10.1053/j.gastro.2006.07.011 1:CAS:528:DC%2BD28XhtFyru7fN
28. DG Ward N Suggett Y Cheng, et al. 2006 Identification of serum biomarkers for colon cancer by proteomic analysis Br J Cancer 94 1898 1905 16755300 10.1038/sj.bjc.6603188 1:CAS:528:DC%2BD28XlsFequ7w%3D
29. L Miguet R Bogumil P Decloquement, et al. 2006 Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS J Proteome Res 5 2258 2269 16944938 10.1021/pr060058y 1:CAS:528:DC%2BD28Xnsl2rurY%3D
30. ET Fung TT Yip L Lomas, et al. 2005 Classification of cancer types by measuring variants of host response proteins using SELDI serum assays Int J Cancer 115 783 789 15704152 10.1002/ijc.20928 1:CAS:528:DC%2BD2MXkvF2ksLw%3D
31. J Song M Patel CN Rosenzweig, et al. 2006 Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay Clin Chem 52 1045 1053 16574760 10.1373/clinchem.2005.065722 1:CAS:528:DC%2BD28XltlSrtb4%3D
32. J Villanueva DR Shaffer J Philip, et al. 2006 Differential exoprotease activities confer tumor-specific serum peptidome patterns J Clin Invest 116 271 284 16395409 10.1172/JCI26022 1:CAS:528:DC%2BD28XjslOgtQ%3D%3D
33. RE Banks AJ Stanley DA Cairns, et al. 2005 Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry Clin Chem 51 1637 1649 16002455 10.1373/clinchem.2005.051417 1:CAS:528:DC%2BD2MXps1yktbw%3D
34. A Karsan BJ Eigl S Flibotte, et al. 2005 Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis Clin Chem 51 1525 1528 15951319 10.1373/clinchem.2005.050708 1:CAS:528: DC%2BD2MXmvV2gsbw%3D
35. JY Engwegen M Alberts JC Knol, et al. 2008 Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer Proteomics Clin Appl 2 936 945 21136891 10.1002/prca.200780068 1:CAS:528:DC%2BD1cXotF2nsrg%3D
36. MC Gast CH van Gils LF Wessels, et al. 2009 Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS) Clin Chem Lab Med 47 694 705 19416081 10.1515/CCLM.2009.151 1:CAS:528:DC%2BD1MXosFKrtLg%3D
37. SY Hsieh RK Chen YH Pan HL Lee 2006 Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling Proteomics 6 3189 3198 16586434 10.1002/pmic.200500535 1:CAS:528:DC%2BD28XlsFagt7Y%3D
38. JF Timms E Arslan-Low A Gentry-Maharaj, et al. 2007 Preanalytic influence of sample handling on SELDI-TOF serum protein profiles Clin Chem 53 645 656 17303688 10.1373/clinchem.2006.080101 1:CAS:528:DC%2BD2sXksFWhtb4%3D
39. L Diao CH Clarke KR Coombes, et al. 2011 Reproducibility of SELDI spectra across time and laboratories Cancer Inform 10 45 64 21552492 1:CAS:528:DC%2BC3MXltlGrt7c%3D
40. DF Ransohoff 2005 Bias as a threat to the validity of cancer molecular-marker research Nat Rev Cancer 5 142 149 15685197 10.1038/nrc1550 1:CAS:528:DC%2BD2MXoslKrsA%3D%3D
41. EP Diamandis 2004 Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations Mol Cell Proteomics 3 367 378 14990683 10.1074/mcp.R400007-MCP200 1:CAS:528: DC%2BD2cXivFCksLo%3D
42. Y Benjamini Y Hochberg 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Stat Soc B 57 289 300
43. R Clarke HW Ressom A Wang, et al. 2008 The properties of high-dimensional data spaces: implications for exploring gene and protein expression data Nat Rev Cancer 8 37 49 18097463 10.1038/nrc2294 1:CAS:528:DC%2BD2sXhsVKku73N
44. MC Gast EJ van Dulken TK van Loenen, et al. 2009 Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling Int J Biol Markers 24 130 141 19787623 1:CAS:528:DC%2BC3cXjvVWiuw%3D%3D
45. JY Engwegen HH Helgason A Cats, et al. 2006 Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry World J Gastroenterol 12 1536 1544 16570345 1:CAS:528:DC%2BD28XksFCrsLg%3D
46. JY Engwegen N Mehra JB Haanen, et al. 2007 Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations Lab Invest 87 161 172 17318195 10.1038/labinvest.3700503 1:CAS:528:DC%2BD2sXitVGrsL0%3D
47. SA Hoffman WA Joo LA Echan DW Speicher 2007 Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma J Chromatogr B 849 43 52 10.1016/j.jchromb.2006. 10.069 1:CAS:528:DC%2BD2sXjvFeit7o%3D
48. ER Galvao LM Martins JO Ibiapina HM Andrade SJ Monte 2011 Breast cancer proteomics: a review for clinicians J Cancer Res Clin Oncol 137 915 925 21465318 10.1007/s00432-011-0978-0 1:CAS:528:DC%2BC3MXlvFyjs74%3D
49. J Solassol P Marin E Demettre, et al. 2005 Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection Anal Biochem 338 26 31 15707932 10.1016/j.ab.2004.11.031 1:CAS:528:DC%2BD2MXhtlenurg%3D
50. J Villanueva A Nazarian K Lawlor P Tempst 2009 Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry Nat Protoc 4 1167 1183 19617888 10.1038/nprot.2009.88 1:CAS:528:DC%2BD1MXpt1Wgs78%3D
51. J Villanueva A Nazarian K Lawlor SS Yi RJ Robbins P Tempst 2008 A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery Mol Cell Proteomics 7 509 518 17986438 1:CAS:528: DC%2BD1cXjsFygtrY%3D
52. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 10963602 10.1038/35021093 1:CAS:528: DC%2BD3cXmt1CnsLw%3D
53. B Weigelt FL Baehner JS Reis-Filho 2009 The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade J Pathol 220 263 280
54. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D
55. A Mackay B Weigelt A Grigoriadis, et al. 2011 Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement J Natl Cancer Inst 103 662 673 21421860 10.1093/jnci/djr071 1:CAS:528:DC%2BC3MXltlejtbs%3D
56. AW Opstal-van Winden EJ Krop MH Karedal, et al. 2011 Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study BMC Cancer 11 381 21871081 10.1186/1471-2407-11-381 1:CAS:528:DC%2BC3MXht1Wrt7rK
57. JY Engwegen MC Gast JH Schellens JH Beijnen 2006 Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry Trends Pharmacol Sci 27 251 259 16600386 10.1016/j.tips.2006.03.003 1:CAS:528:DC%2BD28XksVCmtbo%3D
58. JM Schwenk M Gry R Rimini M Uhlen P Nilsson 2008 Antibody suspension bead arrays within serum proteomics J Proteome Res 7 3168 3179 18588325 10.1021/pr700890b 1:CAS:528:DC%2BD1cXnvVyqsbg%3D
59. JE Anderson LL Hansen FC Mooren, et al. 2006 Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: towards personalized medicine Drug Resist Updat 9 198 210 17011811 10.1016/j.drup.2006.08.001 1:CAS:528:DC%2BD28Xht1ersL%2FK
60. E Kopf D Zharhary 2007 Antibody arrays: an emerging tool in cancer proteomics Int J Biochem Cell Biol 39 1305 1317 17600752 10.1016/j.biocel.2007. 04.029 1:CAS:528:DC%2BD2sXnslWltL4%3D
61. BK Kim JW Lee PJ Park, et al. 2009 The multiplex bead array approach to identifying serum biomarkers associated with breast cancer Breast Cancer Res 11 R22 19400944 10.1186/bcr2247
62. I van den Broek RW Sparidans JH Schellens JH Beijnen 2010 Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry J Chromatogr B 878 590 602 10.1016/j.jchromb.2010.01.011
63. AW van Winden I van den Broek MC Gast, et al. 2010 Serum degradome markers for the detection of breast cancer J Proteome Res 9 3781 3788 20557135 10.1021/pr100395s
64. A Ghazalpour B Bennett VA Petyuk, et al. 2011 Comparative analysis of proteome and transcriptome variation in mouse PLoS Genet 7 e1001393 21695224 10.1371/journal.pgen.1001393 1:CAS:528:DC%2BC3MXnslCnsLs%3D
65. Q Shi LN Harris X Lu, et al. 2006 Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery J Proteome Res 5 2947 2955 17081046 10.1021/pr060099u 1:CAS:528:DC%2BD28XhtVSnsbbN